BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34147031)

  • 21. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.
    Reeb AN; Li W; Sewell W; Marlow LA; Tun HW; Smallridge RC; Copland JA; Spradling K; Chernock R; Lin RY
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E232-42. PubMed ID: 25423568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
    Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma.
    Wu M; Liu Y; Zhao Y; Zhang Y; Huang L; Du Q; Zhang T; Zhong Z; Luo H; Xiao K
    J Vis Exp; 2023 Jun; (196):. PubMed ID: 37335092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
    Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
    Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
    Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
    Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis.
    Zhang H; Yu Y; Zhang K; Liu X; Dai Y; Jiao X
    Bioengineered; 2019 Dec; 10(1):306-315. PubMed ID: 31299871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
    Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
    Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
    Fuziwara CS; Saito KC; Kimura ET
    Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
    [No Abstract]   [Full Text] [Related]  

  • 35. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
    Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 37. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.
    Onoda N; Nakamura M; Aomatsu N; Noda S; Kashiwagi S; Hirakawa K
    World J Surg; 2014 Mar; 38(3):688-95. PubMed ID: 24357248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
    Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
    von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
    J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.